Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 5Small Cell Lung Carcinoma 3Urinary Bladder Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Lung Diseases 1HRD Cancer 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Paclitaxel 12pembrolizumab 7Carboplatin 7Cisplatin 6Docetaxel 5sargramostim 4Taxes 4Cyclophosphamide 4Amifostine 4Trastuzumab 3Polymerase Chain Reaction 3Nivolumab 3Irinotecan 3Gemcitabine 3Etoposide 3talazoparib 2aldesleukin 2Vorinostat 2Vinorelbine 2SS1(dsFv)PE38 2Pemetrexed 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Erlotinib Hydrochloride 2tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × sacituzumab govitecan × Thoracic × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡